Bradley J. Cook - Boulder CO, US Dan J. Welch - Boulder CO, US
Assignee:
Structural Components LLC - Boulder CO
International Classification:
E02D 27/32 E04C 3/00 B65D 19/00 F16B 5/00
US Classification:
52296, 52848, 24834601, 403335
Abstract:
An apparatus for inline base termination of a monopole structure includes an upper base plate configured to be joined to a bottom end of a monopole, a lower base plate including a plurality of bolt holes, and a plurality of web plates connecting the upper and lower base plates, such that a virtual projection of the monopole through the lower base plate intersects the plurality of bolt holes. Another inline base termination apparatus includes a hollow monopole with outer shell, a base plate having a plurality of bolt holes formed therein in a circular pattern and evenly circumferentially spaced, and a plurality of web plates, each of which has a longitudinal slot configured to receive the monopole and is joined to the base plate between two adjacent bolt holes, such that a virtual projection of the hollow monopole through the base plate intersects the plurality of bolt holes.
Bradley J. Cook - Boulder CO, US Dan J. Welch - Boulder CO, US
Assignee:
STRUCTURAL COMPONENTS LLC - Boulder CO
International Classification:
E04H 12/02 H01Q 1/12 E06C 1/00 E04H 12/18
US Classification:
5265107, 343891, 182194
Abstract:
A tower according to embodiments of the present invention includes a monopole shell having a vertical axis, the vertical axis substantially aligned with a gravitational force, wherein at least a portion of the monopole shell has an aerodynamic shape, wherein an outer perimeter of the aerodynamic shape comprises a leading edge and a trailing edge, wherein a chord between the leading edge and the trailing edge is shorter than a distance along the outer perimeter between the leading edge and the trailing edge, and wherein a maximum dimension of the outer perimeter measured orthogonally to the chord and the vertical axis is shorter than the chord; and a base, wherein the monopole shell rotates about the vertical axis with respect to the base.
Swedish Medical GroupSwedish Spine Sport & Musculoskeletal Medicine 1750 112 Ave NE STE D258, Bellevue, WA 98004 4254982272 (phone), 4254982334 (fax)
Education:
Medical School University of Michigan Medical School Graduated: 1978
Procedures:
Neurological Testing
Languages:
English
Description:
Dr. Welch graduated from the University of Michigan Medical School in 1978. He works in Bellevue, WA and specializes in Physical Medicine & Rehabilitation. Dr. Welch is affiliated with Overlake Hospital Medical Center.
Conneaut Lake High School Conneaut Lake PA 1980-1990, Cochranton Junior-Senior High School Cochranton PA 1980-1995, Randolph Elementary School Guys Mills PA 1983-1984, Cambridge Springs Joint High School Cambridge Springs PA 1987-1990, Maplewood High School Guys Mills PA 1987-1990
Additionally, we've always felt Roche could have an interest in AveXis given its development program with RG7916 (another oral administered SMN2 splicing modifier) and the fact that AveXischairman Dan Welch was the CEO of Intermune when Roche purchased Intermune in 2014," Jefferies analysts wrote
Date: Apr 09, 2018
Category: Business
Source: Google
Roche's $8.3 bn deal to buy InterMune to strengthen respiratory portfolio
Commenting on the transaction, Dan Welch, Chairman, CEO and President, InterMune, said, Roche shares our passion and commitment to the IPF community and to ensuring that pirfenidone is available as quickly as possible to patients in the US, pending FDA approval. Roches global resources and s
Date: Aug 26, 2014
Category: Business
Source: Google
Roche ready to roll on InterMune's lung drug with $8.6B buyout deal
global resources and scale" will make it easier--and faster-- to roll out Esbriet in the U.S. and beyond, InterMune CEO Dan Welch said in a statement. "Roche shares our passion and commitment to the IPF community and to ensuring that pirfenidone is available as quickly as possible to patients in the U.
Date: Aug 25, 2014
Source: Google
Roche paying $8.3 billion for InterMune and its 'breakthrough' respiratory drugs
Roche shares our passion and commitment to the IPF community and to ensuring that pirfenidone is available as quickly as possible to patients in the United States, pending FDA approval, said Dan Welch, InterMune CEO.
Date: Aug 25, 2014
Category: Business
Source: Google
Boehringer, InterMune wow IPF field with a slate of groundbreaking trial data
"The study results provide strong evidence of pirfenidone's robust treatment effects and augment its already well-established safety and tolerability profile," sats InterMune CEO Dan Welch. "We currently intend to resubmit the pirfenidone New Drug Application to the U.S. Food and Drug Administration
Date: May 19, 2014
Category: Health
Source: Google
InterMune pulmonary fibrosis drug receives EU approval
InterMune CEO, chairman and president Dan Welch said the company's leadership team in the EU was working diligently to make Esbriet available to European patients, beginning with Germany as early as September 2011.